Benjamin T. Dake, SEE REMARKS at Aerovate Therapeutics, Inc. (AVTE), sold 22,136 shares at $27.97 ($619K) on 2024-03-27, disclosed to the SEC on 2024-03-28.
Scheduled sale ($619k) by SEE REMARKS under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $27.97 | 11,068 | $310K | 50.0% |
| 2 | $27.97 | 11,068 | $310K | 50.0% |
| Total | $27.97 avg | 22,136 | $619K | 100% |
| Filing → |
| AVTE | SELL | 2024-03-27 | $192K | — | Filing → |
| AVTE | SELL | 2024-03-20 | $1.8M | — | Filing → |
| AVTE | SELL | 2023-12-07 | $331K | — | Filing → |